Polymer chelator conjugates
Provided herein are biocompatible polymer conjugates comprising a biologically compatible polymer covalently bound to a biologically compatible chelator moiety, which in turn are optionally bound, reversibly, to pharmacologically active metal ions. The biologically compatible polymer may comprise of modified placental tissue grafts composed of at least one membrane, capable of recruiting stem cells in vivo and in vitro.
1. A biologically compatible polymer-chelator conjugate comprising a biologically compatible non-cross-linked polymer and one or more chelating moieties selected from the group consisting of nordihydroguaiaretic acid (NDGA), 3,4-diyhydroxyphenylalanine, dopamine, 3,4-dihydroxybenzaldehyde, 3,4-dihydroxybenzoic acid, a precursor compound having the structure
a precursor compound having the structure
a precursor compound having the structure
a precursor compound having the structure
a precursor compound having the structure
a precursor compound having the structure
and a precursor compound having the structure
where X in each of said precursor compound structure is a complementary reactive functional group which covalently links said chelating moiety to said polymer, wherein the chelating polymer is non-cross-linked.
2. The conjugate of claim 1 , wherein said conjugate is chelated with a pharmacologically active metal ion.
3. The conjugate of claim 2 , wherein the pharmacologically active metal ion is selected from the group consisting of silver ions, copper ions and platinum ions.
4. The conjugate of claim 3 , wherein the platinum ion is Pt +2 .
5. The conjugate of claim 3 , wherein the ionic platinum is cis-platin.
6. The conjugate of claim 1 , wherein the biocompatible non-cross-linked polymer is collagen.
7. The conjugate of claim 1 , wherein the biocompatible non-cross-linked polymer comprises placental tissue.
8. The conjugate of claim 7 , wherein the placental tissue comprises amnion or chorion.
9. The conjugate of claim 7 , wherein the placental tissue comprises amnion.
10. The conjugate of claim 9 , wherein the placental tissue has a mass sufficient to recruit stem cells to a body part to be treated.
11. A method of manufacturing a medical construct comprising:
providing a construct with a biologically compatible non-cross-linked polymer;
contacting the biologically compatible polymer with chelating moieties to chemically bind the chelating moieties to the biologically compatible non-cross-linked polymer and to provide a polymer-chelator conjugate, wherein the chelating moieties are selected from the group consisting of nordihydroguaiaretic acid (NDGA), 3,4-dyhydroxyphenylalanine, dopamine, 3,4-dihydroxybenzaldehyde, 3,4-dihydroxybenzoic acid, a precursor compound having the structure
a precursor compound having the structure
a precursor compound having the structure
a precursor compound having the structure
a precursor compound having the structure
a precursor compound having the structure
and a precursor compound having the structure
where X in each of said precursor compound structure is a complementary reactive functional group which covalently links said chelating moiety to said polymer, wherein the chelating polymer is non-cross-linked; and
chelating the polymer-chelator conjugate with a pharmacologically active metal ion, thereby producing a medical construct with an incorporated pharmacologically active metal ion.
12. The method of claim 11 , wherein the biocompatible non-cross-linked polymer is collagen.
13. The method of claim 11 , wherein the pharmacologically active metal ion comprises cis-platin.
14. A method for treating cancer amenable to treatment with cis-platin, said method comprising contacting said cancer with a sufficient amount of the conjugate of claim 5 .